Developer of novel engineered compounds designed to corneal dystrophies, improve human health and create new therapies using drugs developed with protein engineering. The company's therapeutic application is developed using a regenerative approach based on novel engineered derivatives of fibroblast growth factor-1 (eFGF-1) to treat endothelial cell mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases.